TGFB1 and neoplasm: This success was due in part to the strong CTL response that the immune system is capable of exhibiting in this scenario, and the complementary nature at work of the two treatment modalities: a boosting of the CTL response coupled with a reduction of tumor angiogenesis and immunosuppression exerted by TGF-β.